Department of Clinical Pharmacology, Emeritus Scientist, ICMR, New Delhi, India.
Department of Clinical Pharmacology, TN Medical College and BYL Nair Hospital, Mumbai, Maharashtra, India.
Indian J Ophthalmol. 2022 Oct;70(10):3687-3689. doi: 10.4103/ijo.IJO_1169_22.
Dry eye syndrome (DES) is a common disorder with rising incidence due to increased use of digital devices. While multiple treatment options are available, some are not efficacious or sometimes even safe for use in DES. This is particularly true for Fixed Dose Combinations (FDCs) that may contain ingredients having no rational for their use or may actually be harmful. Various committees appointed by the Government have reviewed several FDCs marketed in India and found some of them to be irrational and recommended for their removal. This paper discusses the contents of some of these FDCs marketed for DES with an aim to ensure that prescribers are mindful of their ingredients and whether there is adequate data about their efficacy and safety and prescribe them only if they consider them necessary for managing the patient.
干眼症（DES）是一种常见疾病，由于数字设备使用的增加，其发病率呈上升趋势。虽然有多种治疗方法可供选择，但有些方法在 DES 中并不有效，甚至有时不安全。对于固定剂量组合（FDC）尤其如此，这些组合可能含有没有合理使用依据的成分，或者实际上可能有害。政府任命的各种委员会审查了在印度销售的几种 FDC，发现其中一些是不合理的，并建议将其撤出。本文讨论了一些 marketed 用于 DES 的这些 FDC 的内容，目的是确保处方者注意到它们的成分，以及是否有足够的数据证明它们的疗效和安全性，并仅在认为它们对管理患者有必要时才开处方。
